CombiGene AB engages in the development of new treatment for neurological diseases. It focuses on the research of therapy for patients with epilepsy. The company was founded by Lars Thunberg, Merab Kokaia and David Woldbye in 1990 and is headquartered in Lidingoe, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company